For patients with localized prostate cancer, androgen deprivation therapy may be harmful
the ONA take:
According to a new study published in the Journal of OncoTargets and Therapy, researchers from Tulane University in New Orleans, Louisiana, have found that primary androgen deprivation therapy (PADT) was linked with increased all-cause mortality and prostate cancer-specific mortality when compared with radical prostatectomy among men with clinically localized prostate cancer.
For the study, researchers identified 1,624 men diagnosed with clinically localized prostate cancer who underwent PADT and 1,624 men with clinically localized prostate cancer who underwent a radical prostatectomy.
Of the 1,624 patients who received PADT, about 16% died of any cause and 4% died specifically from prostate cancer. of the 1,624 men who opted for radical prostatectomy, about 3% died of any cause and 0.25% died specifically from prostate cancer. The researchers found that the 8-year survival rate among patients who received PADT was approximately 44% and 80% in the radical prostatectomy group.
The findings suggest that PADT was associated with a higher all-cause and prostate cancer-specific mortality compared with radical prostatectomy in patients with clinically localized prostate cancer. Therefore, PADT may not be a good choice as treatment for patients with localized prostate cancer.
Primary ADT linked with increased all-cause mortality and prostate cancer-specific mortality.
A widely used treatment for prostate cancer may cause more harm than good for some patients, according to Dr. Oliver Sartor, medical director of the Tulane Cancer Center. For decades, many men diagnosed with prostate cancer were treated with androgen deprivation therapy (ADT), injections that suppressed testosterone production.
Sartor's research has revealed and a new study corroborates this is the wrong approach for selected men with localized disease, as it provides no added survival benefit and may be associated with other serious health issues.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genetic Similarity to BRCA1/BRCA2 Mutations May Impact Treatment Options
- Evidenced-Based Radiation Treatment Tied to Cost Savings in Early Stage Breast Cancer
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|